

## Platform Specialty Products Corporation Announces 2016 Fourth Quarter and Full Year Financial Performance

- | 2016 net sales of \$3.6 billion, an increase of 41.0%; record net sales of \$950 million in Q4 2016
- | FY and Q4 2016 organic sales increase of 2.0% and 4.6%, respectively
- | 2016 GAAP basic EPS loss of \$0.14 or \$0.63 fully diluted
- | FY and Q4 2016 adjusted EPS of \$0.63 and \$0.20, respectively
- | 2016 GAAP net loss of \$35 million
- | 2016 Adjusted EBITDA of \$769 million, an increase of 35.5%
- | Announcing 2017 Adjusted EBITDA guidance range of \$800 million to \$830 million

WEST PALM BEACH, Fla., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Platform Specialty Products Corporation (NYSE:PAH) ("Platform" or the "Company"), a global, diversified specialty chemicals company, today announced unaudited financial highlights for the three and twelve months ended December 31, 2016.

### Fourth Quarter 2016 Highlights:

- | Net sales on a reported basis for the fourth quarter of 2016 were a record \$950 million, an increase of 29.2% over last year. On a comparable basis, organic sales, which excludes the impact of currency changes, metals prices, acquisitions and divestitures, increased 4.6% quarter-over-quarter;
  - | MacDermid Performance Solutions (Performance Solutions segment): Net sales were \$457 million, an increase of 76.4% compared to the same period of 2015. On a comparable basis, organic sales increased 6.3% quarter-over-quarter
  - | Arysta LifeScience (Agricultural Solutions segment): Net sales were \$493 million, an increase of 3.6% compared to the same period of 2015. On a comparable basis, organic sales increased 3.1% quarter-over-quarter
- | Reported net income attributable to common stockholders was \$4 million, compared to a net loss of \$130 million for the same period in 2015. Diluted earnings per share were \$0.01 on a GAAP basis compared to a diluted loss per share of \$0.60 in the same period of 2015;
- | Adjusted earnings per share were \$0.20 compared to comparable adjusted earnings per share of \$0.14 in the same period of 2015;
- | Adjusted EBITDA for the fourth quarter of 2016 was \$218 million, an increase of 18.7% on a comparable constant currency basis over the fourth quarter of 2015. Adjusted EBITDA margin for the combined company was 23.0% compared to comparable adjusted EBITDA margin of 20.3% in 2015;
- | Additional cost synergies of \$19 million were reported in the fourth quarter of 2016 from on-going integrations.

### Full Year 2016 Highlights:

- | Net sales were \$3.6 billion compared to \$2.5 billion in 2015, an increase of 41.0%. On a comparable basis, organic sales increased 2.0% year-over-year;
  - | MacDermid Performance Solutions (Performance Solutions segment): Net sales were \$1.8 billion, an increase of 121% compared to 2015. On a comparable basis, organic sales increased 1.0% year-over-year
  - | Arysta LifeScience (Agricultural Solutions segment): Net sales were \$1.8 billion, an increase of 4.3% compared to 2015. On a comparable basis, organic sales increased 3.0% year-over-year
- | Reported net loss attributable to common stockholders was \$35 million, compared to a net loss of \$309 million in 2015. Diluted loss per share were \$0.63 on a GAAP basis compared to a diluted loss per share of \$1.52 in 2015;
- | Adjusted earnings per share were \$0.63 compared to comparable adjusted earnings per share of \$0.60 in 2015;
- | Adjusted EBITDA for the year of 2016 was \$769 million, an increase of 5.8% on a comparable constant currency basis. Adjusted EBITDA margin for the combined company was 21.5% compared to comparable adjusted EBITDA margin of 20.5% in 2015;
- | Additional cost synergies of \$60 million were reported in 2016 from the ongoing integrations in both the Agricultural Solutions and Performance Solutions segments. The Company considers the Agricultural Solutions integration to be effectively complete, having actioned \$85 million of estimated synergies on an annualized, run rate basis to date.

### Executive Commentary

Platform's Chief Executive Officer Rakesh Sachdev stated: "2016 was a successful year for Platform in a number of ways. Our revenue growth accelerated significantly in the second half of the year, and our business overall demonstrated

resilience in mixed end markets. We exceeded our adjusted EBITDA target, generating comparable adjusted EBITDA growth of nearly 6% for the full year on a constant currency basis. Our strong earnings translated into cash flow from operations of \$185 million. Furthermore, we improved our balance sheet meaningfully with the settlement of all our obligations related to our Series B convertible preferred stock, which resulted in savings of approximately \$100 million, and the repricing of all of our term loans, which we expect to generate annual interest savings of \$26 million. Finally, we stabilized our management team with a number of key hires who have already made significant contributions to the Company.

Our 2017 guidance and outlook calls for expected adjusted EBITDA of \$800 to \$830 million and organic earnings growth in both segments. While we anticipate certain global and regional headwinds, we still expect to achieve above market growth in both our businesses. We also plan to deliver further meaningful cost synergies in the Performance Solutions segment and supply chain savings in the Agricultural Solutions segment. At the mid-point, our adjusted EBITDA guidance implies growth of 8% over 2016 on a constant currency basis and is in line with our long term expectations."

### **2017 Guidance**

Based on foreign exchange rates as of January 31, 2017, Platform expects adjusted EBITDA for 2017 in the range of \$800 million to \$830 million, representing an increase of 8% at the mid-point on a constant currency basis.

### **2016 Form 10-K Filing**

Platform expects to avail itself of the 15-day filing extension available under Rule 12b-25 to file its annual report on Form 10-K for the fiscal year ended December 31, 2016. As part of Platform's continued integration of its Performance Solutions and Agricultural Solutions segments, the Company has an ongoing initiative to simplify its corporate and tax footprint to better manage cash taxes and its overall cash position. As a result of the timing and scale of legal entity combinations involved in this initiative, Platform has not yet completed certain tax procedures and related disclosure to be included in its Form 10-K. These items are not expected to impact the financial information presented in this release. Once these items are finalized, Platform expects to file its annual report on Form 10-K with its audited financial statements for the fiscal year ended December 31, 2016 within the permitted extension period.

Platform previously reported material weaknesses which, at the date hereof, remain unremediated. Platform will complete the assessment of the effectiveness of its internal control over financial reporting prior to the filing of the Form 10-K.

### **Conference Call**

Platform will host a webcast/dial-in conference call to discuss its 2016 fourth quarter and full year financial performance at 8:30 a.m. (Eastern Time) on Tuesday, February 28, 2017. Participants on the call will include Rakesh Sachdev, Chief Executive Officer; Sanjiv Khattri, Chief Financial Officer; and Benjamin Gliklich, Executive Vice President - Operations and Strategy.

To listen to the call by telephone, please dial (855) 357-3116 (domestic) or (484) 365-2867 (international) and provide the Conference ID: 74692869. The call will be simultaneously webcast at [www.platformspecialtyproducts.com](http://www.platformspecialtyproducts.com). A replay of the webcast will be available for three weeks shortly after completion of the live call at [www.platformspecialtyproducts.com](http://www.platformspecialtyproducts.com).

### **Non-GAAP Financial Measures**

This release and its attachments contains non-GAAP financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission, including adjusted EBITDA, adjusted EBITDA margin, adjusted EBITDA guidance, comparable net sales, comparable adjusted earnings per share, comparable adjusted EBITDA, comparable adjusted EBITDA margin, organic sales and free cash flow. Please refer to *VI. Non-GAAP Measures* for definitions and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP.

### **About Platform**

Platform is a global, diversified producer of high-technology specialty chemicals and provider of technical services. The business involves the formulation of a broad range of solutions-oriented specialty chemicals, which are sold into multiple industries, including automotive, agriculture, animal health, electronics, graphic arts, and offshore oil and gas production and drilling. More information on Platform is available at [www.platformspecialtyproducts.com](http://www.platformspecialtyproducts.com).

### **Forward-Looking Statements**

This release contains statements which are, or may be deemed to be, "forward-looking statements" which are prospective in nature. All statements other than statements of historical facts are forward-looking statements. They are based on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations and include, but are not limited to, statements relating to: (i) Platform's ability to file its 2016 Form 10-K within the 15-day extended filing deadline; (ii) estimated or expected net sales, adjusted EBITDA, adjusted earnings per share, organic growth, synergies, free cash flow, future capital expenditures, expenses, earnings, economic performance, indebtedness, financial condition, income tax provision, dividend policy, losses and future prospects; (iii) business and management strategies; and (iv) the effects of global economic conditions on Platform's business. Many of these important factors are outside of Platform's control. No assurances can be provided as to any result or the timing of any outcome regarding matters described herein or otherwise. Such statements are based on management's estimates and assumption with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Many factors may cause the actual results, performance or achievements of Platform to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements of Platform to differ materially from the expectations of Platform include, among other things: (i) Platform's perception of future availability of equity or debt financing needed to fund its growing business; (ii) Platform's assessment of its internal control over financial reporting; (iii) Platform's ability to identify, hire and retain executives and other employees with sufficient expertise; (iv) the impact of commodities and currencies and Platform's ability to manage its risk in these areas; (v) future capital expenditures, indebtedness, leverage, and dividend policy; (vi) general business and economic conditions globally, industry trends, competition, government investigations, litigation, changes in government and other regulations, changes in political and economic stability, disruptions in business operations due to re-organization activities; (vii) interest rate and currency fluctuations; and (viii) the impact of acquisitions, divestitures, restructuring, refinancing, and other unusual items, including Platform's ability to successfully complete as well as integrate and obtain the anticipated results and synergies from its acquisitions. Other risk factors are described in Platform's periodic and other reports filed with the Securities and Exchange Commission, including Platform's annual report on Form 10-K for the fiscal year ended December 31, 2015 and quarterly reports on Form 10-Q for the fiscal quarters ended March 31, 2016, June 30, 2016 and September 30, 2016, as well as any subsequent reports on Forms 10-K, 10-Q and 8-K, which are or will be available at [www.platformspecialtyproducts.com](http://www.platformspecialtyproducts.com).

This release is intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995 as it contains "forward-looking statements" within the meaning of the federal securities laws. Platform and its associates, directors, officers and advisers do not provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this release will actually occur. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Platform undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

-FINANCIAL TABLES TO FOLLOW-

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Unaudited)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2016	2015	2016	2015
<i>(amounts in millions, except per share amounts)</i>				
<b>Net sales</b>	\$ 950	\$ 735	\$ 3,586	\$ 2,542
Cost of sales	554	462	2,078	1,550
<b>Gross profit</b>	396	273	1,508	992
Operating expenses:				
Selling, technical, general and administrative	300	264	1,123	858
Research and development	23	15	84	63
Goodwill impairment	47	—	47	—
Total operating expenses	370	279	1,254	920
<b>Operating profit</b>	26	(6)	253	72
Other (expense) income:				
Interest expense, net	(86)	(71)	(376)	(214)
Loss on derivative contracts	—	(24)	(13)	(74)
Foreign exchange gain (loss)	42	(24)	(14)	(43)

Other (expense) income, net	(20)	11	101	30
Total other expense	(64)	(108)	(302)	(301)
Loss before income taxes and non-controlling interests	(37)	(114)	(48)	(229)
Income tax benefit (expense)	43	(15)	(22)	(75)
<b>Net income (loss)</b>	6	(130)	(71)	(304)
Net loss (income) attributable to the non-controlling interests	(2)	—	3	(4)
<b>Net income (loss) attributable to stockholders</b>	4	(130)	(68)	(309)
Gain on amendment of Series B Convertible Preferred Stock	—	—	33	—
<b>Net income (loss) attributable to common stockholders</b>	<u>\$ 4</u>	<u>\$ (130)</u>	<u>\$ (35)</u>	<u>\$ (309)</u>
<b>Earnings (loss) per share attributable to common stockholders</b>				
Basic	\$ 0.02	\$ (0.60)	\$ (0.14)	\$ (1.52)
Diluted	\$ 0.01	\$ (0.60)	\$ (0.63)	\$ (1.52)
<b>Weighted average common shares outstanding</b>				
Basic	280	217	243	203
Diluted	290	217	272	203

NOTE: Totals may not foot due to rounding

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**CONSOLIDATED BALANCE SHEETS**  
(Unaudited)

<i>(amounts in millions)</i>	<u>December 31, 2016</u>	<u>December 31, 2015</u>
<b>Assets</b>		
Cash and cash equivalents	\$ 423	\$ 432
Accounts receivable, net of allowance for doubtful accounts of \$37 and \$14 at December 31, 2016 and 2015, respectively	1,055	1,023
Inventories	416	485
Note receivable	—	125
Prepaid expenses	71	72
Other current assets	106	101
<b>Total current assets</b>	<u>2,071</u>	<u>2,238</u>
Property, plant and equipment, net	461	492
Goodwill	4,166	4,022
Intangible assets, net	3,233	3,314
Other assets	110	125
<b>Total assets</b>	<u>\$ 10,041</u>	<u>\$ 10,190</u>
<b>Liabilities &amp; Stockholders' Equity</b>		
Accounts payable	\$ 384	\$ 450
Accrued salaries, wages and employee benefits	104	78
Current installments of long-term debt and revolving credit facilities	116	55
Accrued income taxes payable	83	65
Accrued expenses and other current liabilities	397	414
<b>Total current liabilities</b>	<u>1,083</u>	<u>1,062</u>
Long-term debt and capital lease obligations	5,123	5,174
Long-term retirement benefits, less current portion	74	81
Long-term deferred income taxes	644	679
Long-term contingent consideration	76	71

Other long-term liabilities	146	205
<b>Total liabilities</b>	<u>7,145</u>	<u>7,271</u>
Commitments and contingencies		
Redeemable preferred stock - Series B	—	646
<b>Stockholders' Equity</b>		
Preferred stock - Series A	—	—
Common stock, 400 shares authorized, 284 and 229 shares issued and outstanding at December 31, 2016 and 2015, respectively.	3	2
Additional paid-in capital	3,981	3,520
Accumulated deficit	(567)	(533)
Accumulated other comprehensive loss	(675)	(886)
<b>Total stockholders' equity</b>	<u>2,742</u>	<u>2,104</u>
Non-controlling interests	154	169
<b>Total equity</b>	<u>2,896</u>	<u>2,273</u>
<b>Total liabilities, redeemable preferred shares and stockholders' equity</b>	<u>\$ 10,041</u>	<u>\$ 10,190</u>

NOTE: Totals may not foot due to rounding

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited)

<i>(amounts in millions)</i>	2016				2015	
	Q1	Q2	Q3	Q4	FY	FY
<b>Cash flows from operating activities:</b>						
Net (loss) income	\$(134)	\$ (8)	\$ 66	\$ 6	\$ (71)	\$ (304)
Reconciliations of net (loss) income to net cash flows (used in) provided by operating activities:						
Depreciation and amortization	83	85	87	87	342	251
Deferred income taxes	(14)	(10)	(34)	(7)	(65)	(46)
Manufacturer's profit in inventory adjustment	12	—	—	—	12	77
Unrealized foreign exchange loss (gain)	62	(28)	14	(4)	44	97
Non-cash fair value adjustment to contingent consideration	3	1	—	1	5	7
Goodwill impairment	—	—	—	47	47	—
Other, net	20	4	(83)	35	(23)	30
Changes in assets and liabilities, net of acquisitions:						
Accounts receivable	(103)	12	29	43	(19)	67
Inventory	(87)	45	7	105	70	(7)
Accounts payable	(39)	(29)	1	(1)	(67)	83
Accrued expenses	(19)	19	10	16	25	52
Other assets and liabilities	6	6	(9)	(119)	(116)	15
Net cash flows (used in) provided by operating activities	<u>(210)</u>	<u>97</u>	<u>89</u>	<u>209</u>	<u>185</u>	<u>321</u>
<b>Cash flows from investing activities:</b>						
Capital expenditures	(12)	(11)	(10)	(24)	(56)	(48)
Investment in registrations of products	(8)	(8)	(7)	(14)	(36)	(34)
Proceeds from sale of assets	2	10	8	—	21	26
Acquisition of business, net of cash acquired	(1)	3	—	—	1	(4,600)
Restricted cash	—	—	—	—	—	600
Note receivable	—	—	—	—	—	(125)
Settlement of foreign exchange contracts in connection with acquisition	—	—	—	—	—	(73)
Other, net	(2)	(4)	2	—	(4)	(1)
Net cash flows used in investing activities	<u>(20)</u>	<u>(10)</u>	<u>(7)</u>	<u>(37)</u>	<u>(75)</u>	<u>(4,257)</u>
<b>Cash flows from financing activities:</b>						
Debt proceeds, net of discount and premium	1	(2)	1	3,301	3,301	3,922
Repayments of borrowings	(9)	(9)	(9)	(3,314)	(3,340)	(284)

Change in lines of credit, net	133	(28)	(85)	35	54	(12)
Proceeds from issuance of common stock, net	—	—	391	—	392	470
Payment of financing fees	—	(1)	—	—	(1)	(87)
Settlement of Series B Convertible Preferred Stock	—	—	—	(460)	(460)	—
Other, net	(4)	(34)	(8)	(1)	(47)	(7)
Net cash flows provided by (used in) financing activities	121	(73)	290	(440)	(102)	4,001
Effect of exchange rate changes on cash and cash equivalents	7	(2)	1	(24)	(18)	(31)
<b>Net (decrease) increase in cash and cash equivalents</b>	(103)	12	372	(292)	(10)	35
Cash and cash equivalents at beginning of period	432	330	342	714	432	397
<b>Cash and cash equivalents at end of period</b>	<u>\$ 330</u>	<u>\$ 342</u>	<u>\$ 714</u>	<u>\$ 423</u>	<u>\$ 423</u>	<u>\$ 432</u>
<b>Supplemental disclosure information:</b>						
Cash paid for interest	<u>\$ 100</u>	<u>\$ 83</u>	<u>\$ 103</u>	<u>\$ 74</u>	<u>\$ 360</u>	<u>\$ 148</u>
Cash paid for income taxes	<u>\$ 26</u>	<u>\$ 28</u>	<u>\$ 32</u>	<u>\$ 35</u>	<u>\$ 121</u>	<u>\$ 73</u>

NOTE: Totals may not foot due to rounding

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**RECONCILIATION OF NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS TO**  
**COMPARABLE ADJUSTED EARNINGS PER SHARE**  
(Unaudited)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2016	2015	2016	2015
<i>(amounts in millions, except per share amounts)</i>				
<b>Net income (loss) attributable to common stockholders</b>	<b>\$ 4</b>	<b>\$ (130)</b>	<b>\$ (35)</b>	<b>\$ (309)</b>
<b>Pre-acquisition activity of acquired companies:</b> (1)				
Net sales	—	171	—	1,077
Cost of sales	—	(100)	—	(642)
Selling, technical, general and administrative expense	—	(77)	—	(321)
Research and development expense	—	(5)	—	(32)
Other income, net	—	2	—	4
	<u>—</u>	<u>(9)</u>	<u>—</u>	<u>86</u>
<b>Adjustments:</b>				
Interest expense for pre-acquisition periods (1)	—	(22)	—	(155)
Reversal of amortization expense (1,2)	68	60	267	216
Adjustment for investment in registration of products (1,2)	(14)	(8)	(36)	(35)
Restructuring expenses (1,3)	12	73	31	108
Manufacturer's profit in inventory purchase accounting adjustments (4)	—	19	12	77
Acquisition and integration costs (5)	6	23	33	93
Non-cash change in fair value of contingent consideration (6)	1	1	5	7
Gain on legal settlement (7)	—	—	(3)	(16)
Foreign exchange loss on foreign denominated external and internal debt (1,8)	(25)	19	34	49
Goodwill impairment (9)	47	—	47	—
Adjustment to reverse loss on derivative contract (10)	—	26	—	74
Gain on settlement agreement related to Series B Convertible Preferred Stock (11)	—	—	(103)	—
Non-cash change in fair value of preferred stock redemption liability (11)	11	—	5	—

Debt refinancing costs	(12)	20	—	20	—
Other expenses (income), net	(13)	11	—	19	(3)
Adjustment to estimated effective tax rate	(14)	(78)	(8)	(76)	(19)
Gain on amendment of Series B Convertible Preferred Stock	(11)	—	—	(33)	—
Adjustment to reverse loss attributable to certain non-controlling interests	(15)	(2)	(1)	(10)	(1)
		<u>57</u>	<u>180</u>	<u>211</u>	<u>393</u>
<b>Comparable adjusted net income attributable to common stockholders</b>		<u>\$ 61</u>	<u>\$ 41</u>	<u>\$ 177</u>	<u>\$ 170</u>
<b>Comparable adjusted earnings per share</b>		<b>\$ 0.20</b>	<b>\$ 0.14</b>	<b>\$ 0.63</b>	<b>\$ 0.60</b>
<b>Adjusted shares outstanding (in millions)</b>	(16)	<b>299</b>	<b>299</b>	<b>282</b>	<b>282</b>

NOTE: Totals may not foot due to rounding

(1) The Company adjusts for the results of operations of Alent plc ("Alent") and the businesses of OM Group, Inc. (the "OMG Businesses"), prior to their acquisition, adjusted to conform with the Company's accounting policies and adjustments described herein, in order to facilitate comparison against prior and future results. The Company also adjusts interest expense to represent the additional interest expense that the Company would have incurred had the acquisition-related debt existed at the beginning of the periods presented in order to be consistent with the inclusion of these results of operations.

(2) The Company eliminates amortization related to intangible assets recognized in purchase accounting for acquisitions and costs capitalized in connection with obtaining regulatory approval of its products ("registration rights") as part of ongoing operations. We deducts capital expenditures associated with obtaining these registration rights. The Company believes these adjustments provide insight with respect to the cash flows necessary to maintain and enhance the Company's product portfolio.

(3) Adjusted for cost of restructuring acquired businesses in both the Agricultural Solutions and Performance Solutions segments. The Company adjusts these costs because they are not reflective of ongoing operations.

(4) Adjustment for purchase accounting fair value adjustment to inventory associated with acquisitions charged to cost of sales primarily related to the acquisitions of Alent (the "Alent Acquisition") and the OMG Businesses (the "OMG Acquisition," and together with the Alent Acquisition, the "Performance Solutions Acquisitions") in 2016 and the acquisitions of Arysta LifeScience Limited (the "Arysta Acquisition") and the Chemtura AgroSolutions business of Chemtura Corporation (the "CAS Acquisition," and together with the Arysta Acquisition, the "Agricultural Solutions Acquisitions") in 2015. The Company adjusts these costs because they are not reflective of ongoing operations.

(5) The Company adjusts for costs associated with acquisitions, including costs of obtaining related financing such as investment banking, legal, and accounting fees, and transfer taxes for 2016 and 2015. 2016 adjustments also include the costs associated with an investigation related to certain past business practices of Arysta, an acquired company, and costs of integrating acquisitions. 2015 adjustments also include a bonus paid to a management member of an acquired company which was tied to the completion the Arysta Acquisition. The Company adjusts these costs because they are not reflective of ongoing operations.

(6) The Company adjusts for the change in fair value of the contingent consideration in connection with the acquisition of MacDermid, Incorporated (the "MacDermid Acquisition"). The Company adjusts these costs because they are not reflective of ongoing operations.

(7) The Company adjusts for certain legal settlements that are not reflective of ongoing operations.

(8) The Company adjusts foreign exchanges gains and losses on intercompany and third-party long-term debt because these changes are out of its control, are expected to largely offset on a long-term basis and, due to their long-term nature are not fully realized. The Company does not exclude foreign exchange gains and losses on short-term intercompany and third-party payables and receivables with third parties.

- (9) The Company recorded a non-cash impairment charge totaling \$47 million related to Performance Solutions' Offshore Solutions reporting unit and has adjusted for the charge because it is not reflective of ongoing operations.
- (10) The Company recorded a loss on a derivative contract used to mitigate foreign currency exposure related to the Alent acquisition and has adjusted for the loss because it is not reflective of ongoing operations.
- (11) The Company accounted for the settlement agreement as an amendment to the Series B convertible preferred stock (the "Series B Convertible Preferred Stock") and, as a result, recognized gains in net income of \$103 million and income available to common stockholders of \$33 million related to the amendment. Further, the Company recognized a loss of \$11 million during Q4 2016, and a loss of \$5 million for the full year 2016, related to the adjustment of the Series B Preferred Stock to fair value subsequent to the amendment. The Company adjusted these gains and losses because they are not representative of ongoing operations. These gains and losses were included in income available to common stockholders for the computation of GAAP basic earnings per share; however, these gains and losses were excluded for purposes of the computation of GAAP diluted earnings per share.
- (12) The Company recorded costs related to its term debt refinancing of \$20 million and has adjusted for such costs because it is not reflective of ongoing operations.
- (13) 2016 adjustments primarily correspond to the sales of a business, a gain on the disposal of an equity investment, and costs associated with non-recourse factoring programs that are not included in interest expense. 2015 adjustment reflects the gain related to the expiration of a put option on Platform's common stock issued in connection with an acquisition during 2014. In addition, the Company adjusts for the portion of long-term compensation plans associated with the Performance Solutions Acquisitions for 2016 and the Agricultural Solutions Acquisitions for 2015. The Company adjusts these costs because they are not reflective of ongoing operations. The Company does not adjust for the cost of ongoing non-acquisition related long-term compensation plans.
- (14) The Company adjusts its effective tax rate to 35%. This adjustment does not reflect the Company's current or near-term tax structure, including limitations on its ability to utilize net operating losses and foreign tax credits in certain jurisdictions. These factors would increase the Company's tax rate above 35%. As a result of its current tax structure, the Company's tax rate in accordance with GAAP was 116% and (46.6)% for the three and twelve months ended December 31, 2016. The Company adjusts to the effective tax rate to provide a meaningful comparison of its performance between periods.
- (15) The Company adjusts for the non-controlling interest expense or income related to the non-controlling interest created at the time of the MacDermid Acquisition because holders of such equity interest are expected to convert their holdings into shares of Platform's common stock. Further, the Company adjusts for the impact a sale of a business has on non-controlling interests. The Company adjusts these costs because they are not reflective of ongoing operations.
- (16) The Company defines "Adjusted shares" for each quarter as the outstanding shares of Platform's common stock at the end of each period plus the number of shares that would be issued if all convertible stock were converted to Platform's common stock, vested stock options were exercised, and awarded equity granted were vested. Adjusted shares outstanding as of December 31, 2016 and 2015 represent the average of the four quarters. The Company adjusts the outstanding shares of Platform's common stock for this calculation to provide an understanding of the Company's results of operations on a comparable per share basis.

#### CALCULATION OF NON-GAAP ADJUSTED SHARES AT DECEMBER 31, 2016 (Unaudited)

<i>(amounts in millions)</i>	<b>Q1 2016</b>	<b>Q2 2016</b>	<b>Q3 2016</b>	<b>Q4 2016</b>	<b>FY Average</b>
<b>Basic outstanding shares</b>	<b>230</b>	<b>230</b>	<b>278</b>	<b>284</b>	<b>255</b>
Number of shares issuable upon conversion of Series B Convertible Preferred Stock	22	22	22	—	17
Number of shares issuable upon conversion of PDH Common Stock	8	8	8	8	8
Number of shares issuable upon conversion of Series A Preferred Stock	2	2	2	2	2
Stock options	1	1	1	1	1
Equity awards granted	4	4	4	4	4



Net impact of pending Series B Convertible Preferred Stock actions	—	—	(17)	—	(4)
<b>Adjusted shares</b>	<b>266</b>	<b>266</b>	<b>299</b>	<b>299</b>	<b>282</b>

NOTE: Totals may not foot due to rounding

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**RECONCILIATION OF ADJUSTED NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS TO COMPARABLE ADJUSTED EBITDA**  
**(Unaudited)**

<i>(amounts in millions)</i>	<b>Three Months Ended December 31,</b>		<b>Twelve Months Ended December 31,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
<b>Comparable adjusted net income attributable to common stockholders</b>	\$ 61	\$ 41	\$ 177	\$ 170
Net income attributable to the non-controlling interests	3	2	7	6
<b>Adjusted net income attributable to stockholders</b>	<b>64</b>	<b>42</b>	<b>184</b>	<b>175</b>
<i>Adjustments to reconcile to comparable adjusted EBITDA:</i>				
Income tax expense	35	23	99	94
Interest expense, net	86	92	376	369
Depreciation expense	19	19	75	68
Investment in registration of products	14	8	36	35
<b>Comparable Adjusted EBITDA</b>	<b>\$ 218</b>	<b>\$ 184</b>	<b>\$ 769</b>	<b>\$ 742</b>

NOTE: Totals may not foot due to rounding

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**RECONCILIATION OF NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS TO ADJUSTED EBITDA**  
**(Unaudited)**

<i>(amounts in millions)</i>	<b>Three Months Ended December 31,</b>		<b>Twelve Months Ended December 31,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
<b>Net income (loss) attributable to common stockholders</b>	\$ 4	\$ (130)	\$ (35)	\$ (309)
Gain on amendment of Series B Convertible Preferred Stock <sup>(11)</sup>	—	—	(33)	—
Net income (loss) attributable to the non-controlling interests	2	—	(3)	4
Income tax (benefit) expense	(43)	15	22	75
<b>Loss before income taxes and non-controlling interests</b>	<b>(37)</b>	<b>(114)</b>	<b>(48)</b>	<b>(229)</b>
<i>Adjustments to reconcile to Adjusted EBITDA:</i>				
Interest expense, net	86	71	376	214
Depreciation expense	19	15	75	49
Amortization expense	68	60	267	202
Restructuring expense <sup>(3)</sup>	12	7	31	25
Manufacturer's profit in inventory purchase accounting adjustments <sup>(4)</sup>	—	19	12	77
Acquisition and integration costs <sup>(5)</sup>	6	52	33	122
Non-cash change in fair value contingent consideration <sup>(6)</sup>	1	1	5	7
Legal settlement <sup>(7)</sup>	—	—	(3)	(16)

Foreign exchange (gain) loss on foreign denominated external and internal debt	(8)	(25)	20	34	46
Fair value loss on foreign exchange forward contract	(10)	—	26	—	74
Goodwill impairment	(9)	47	—	47	—
Gain on settlement agreement related to Series B Convertible Preferred Stock	(11)	—	—	(103)	—
Non-cash change in fair value of preferred stock redemption liability	(11)	11	—	5	—
Debt refinancing costs	(12)	20	—	20	—
Other expense (income), net	(13)	11	—	19	(3)
<b>Adjusted EBITDA</b>		<b>\$ 218</b>	<b>\$ 154</b>	<b>\$ 769</b>	<b>\$ 568</b>

NOTE: Totals may not foot due to rounding

\* See footnote descriptions below the Comparable Adjusted Earnings Per Share table.

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**RECONCILIATION OF REPORTED SEGMENT RESULTS TO COMPARABLE SEGMENT RESULTS**  
**(Unaudited)**

**Three Months Ended December 31,**

<i>(amounts in millions)</i>	<b>Performance Solutions</b>				<b>Agricultural Solutions</b>				<b>Total</b>			
	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>
<b>Net Sales</b>	\$ 457	\$ 259	\$ 198	76%	\$ 493	\$ 476	\$ 17	4%	\$ 950	\$ 735	\$ 215	29%
<b>Acquisitions:</b>												
Alent		152								152		
OM		18								18		
<b>Comparable Net Sales</b>	457	430	27	6%	493	476	17	4%	950	906	44	5%
<b>Organic Sales</b>												
Foreign exchange translation	13	—			(11)	—			1	—		
<b>Constant Currency</b>	470	430	40	9%	482	476	6	1%	951	906	45	5%
Dispositions						(9)				(9)		
Impact of metal prices	(13)	—			—				(13)	—		
<b>Organic Sales Growth</b>	\$ 457	\$ 430	\$ 27	6%	\$ 482	\$ 467	\$ 14	3%	\$ 939	\$ 897	\$ 41	5%

NOTE: Totals may not foot due to rounding

**Three Months Ended December 31,**

<i>(amounts in millions)</i>	<b>Performance Solutions</b>				<b>Agricultural Solutions</b>				<b>Total</b>			
	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>
<b>Adj. EBITDA ex-corp cost</b>	\$ 119	\$ 71	\$ 48	67%	\$ 116	\$ 99	\$ 18	18%	\$ 235	\$ 170	\$ 65	38%
<b>Acquisitions:</b>												
Alent		26								26		
OM		4								4		
<b>Comparable Adj. EBITDA ex-corp costs</b>	119	101	18	18%	116	99	18	18%	235	199	36	18%

Corporate allocations	(8)	(8)			(8)	(8)			(17)	(15)		
<b>Comparable Adj. EBITDA</b>	111	93	17	18%	108	91	17	19%	218	184	34	18%
Foreign exchange translation	5				(4)				—			
<b>Comparable Constant Currency</b>	\$ 115	\$ 93	\$ 22	23%	\$ 104	\$ 91	\$ 13	14%	\$ 219	\$ 184	\$ 34	19%

NOTE: Totals may not foot due to rounding

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**RECONCILIATION OF REPORTED SEGMENT RESULTS TO COMPARABLE SEGMENT RESULTS (continued)**  
(Unaudited)

**Twelve Months Ended December 31, 2016**

<i>(amounts in millions)</i>	<b>Performance Solutions</b>				<b>Agricultural Solutions</b>				<b>Total</b>			
	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>
<b>Net Sales</b>	\$ 1,770	\$ 801	\$ 969	121%	\$ 1,816	\$ 1,742	\$ 74	4%	\$ 3,586	\$ 2,542	\$ 1,044	41%
<b>Acquisitions:</b>												
Alent		847								847		
OM		142								142		
Arysta						87				87		
<b>Comparable Sales</b>	1,770	1,791	(21)	(1)%	1,816	1,829	(13)	(1)%	3,586	3,620	(34)	(1)%
<b>Organic Sales</b>												
Foreign exchange translation	48				36				83	—		
<b>Constant Currency</b>	1,818	1,791	27	2%	1,851	1,829	22	1%	3,669	3,620	49	1%
Acquisitions	3				—				3	—		
Dispositions						(32)			—	(32)		
Impact of metal prices	(13)				—				(13)	—		
<b>Organic Sales Growth</b>	\$ 1,808	\$ 1,791	\$ 17	1%	\$ 1,851	\$ 1,797	\$ 55	3%	\$ 3,659	\$ 3,588	\$ 72	2%

NOTE: Totals may not foot due to rounding

**Twelve Months Ended December 31, 2016**

<i>(amounts in millions)</i>	<b>Performance Solutions</b>				<b>Agricultural Solutions</b>				<b>Total</b>			
	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>	<b>2016</b>	<b>2015</b>	<b>Change</b>	<b>YOY%</b>
<b>Adj. EBITDA ex-corp cost</b>	\$ 434	\$ 236	\$ 198	84%	\$ 401	\$ 379	\$ 22	6%	\$ 835	\$ 616	\$ 220	36%
<b>Acquisitions:</b>												
Alent		143								143		
OM		28								28		
Arysta						3				3		
<b>Comparable Adj. EBITDA ex-corp costs</b>	434	407	27	7%	401	382	19	5%	835	790	45	6%
Corporate allocations	(33)	(24)			(33)	(24)			(66)	(48)		
<b>Comparable Adj. EBITDA</b>	401	384	18	5%	368	358	10	3%	769	742	28	4%
Foreign exchange translation	15				—				16			
<b>Comparable Constant Currency</b>	\$ 417	\$ 384	\$ 33	9%	\$ 369	\$ 358	\$ 10	3%	\$ 785	\$ 742	\$ 43	6%

NOTE: Totals may not foot due to rounding

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**ADDITIONAL FINANCIAL INFORMATION**  
(Unaudited)

<i>(amounts in millions)</i>	<b>Financial Performance</b>			
	<b>Three Months Ended December 31,</b>		<b>Twelve Months Ended December 31,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
<b>Net Sales</b>				
Performance Solutions	\$ 457	\$ 259	\$ 1,770	\$ 801
Agricultural Solutions	493	476	1,816	1,742
<b>Total</b>	<b>\$ 950</b>	<b>\$ 735</b>	<b>\$ 3,586</b>	<b>\$ 2,542</b>
<b>Adjusted EBITDA</b>				
Performance Solutions	\$ 111	\$ 67	\$ 401	\$ 224
Agricultural Solutions	108	87	368	343
<b>Total</b>	<b>\$ 218</b>	<b>\$ 154</b>	<b>\$ 769</b>	<b>\$ 568</b>
<b>Adjusted EBITDA Margin</b>				
Performance Solutions	24.2%	26.0%	22.7%	28.0%
Agricultural Solutions	21.8%	18.3%	20.3%	19.7%
<b>Total</b>	<b>23.0%</b>	<b>21.0%</b>	<b>21.5%</b>	<b>22.3%</b>

NOTE: Totals may not foot due to rounding

<i>(amounts in millions)</i>	<b>Comparable Financial Performance</b>			
	<b>Three Months Ended December 31,</b>		<b>Twelve Months Ended December 31,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
<b>Net Sales</b>				
Performance Solutions	\$ 457	\$ 430	\$ 1,770	\$ 1,791
Agricultural Solutions	493	476	1,816	1,829
<b>Total</b>	<b>\$ 950</b>	<b>\$ 906</b>	<b>\$ 3,586</b>	<b>\$ 3,620</b>
<b>Adjusted EBITDA <sup>(1)</sup></b>				
Performance Solutions	\$ 111	\$ 93	\$ 401	\$ 384
Agricultural Solutions	108	91	368	358
<b>Total</b>	<b>\$ 218</b>	<b>\$ 184</b>	<b>\$ 769</b>	<b>\$ 742</b>
<b>Adjusted EBITDA Margin</b>				
Performance Solutions	24.2%	21.7%	22.7%	21.4%
Agricultural Solutions	21.8%	19.1%	20.3%	19.6%
<b>Total</b>	<b>23.0%</b>	<b>20.3%</b>	<b>21.5%</b>	<b>20.5%</b>

NOTE: Totals may not foot due to rounding

(1) Includes reallocations of corporate overhead costs in 2015.

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**ADDITIONAL FINANCIAL INFORMATION (continued)**  
(Unaudited)

III.  (amounts in millions)	<b>Comparable Constant Currency Financial Performance</b>			
	<b>Three Months Ended December 31,</b>		<b>Twelve Months Ended December 31,</b>	
	<b>2016</b>	<b>2015</b>	<b>2016</b>	<b>2015</b>
<b>Net Sales</b>				
Performance Solutions	\$ 470	\$ 430	\$ 1,818	\$ 1,791
Agricultural Solutions	482	476	1,851	1,829
<b>Total</b>	<b>\$ 951</b>	<b>\$ 906</b>	<b>\$ 3,669</b>	<b>\$ 3,620</b>
<b>Adjusted EBITDA</b>				
Performance Solutions	\$ 115	\$ 93	\$ 417	\$ 384
Agricultural Solutions	104	91	369	358
<b>Total</b>	<b>\$ 219</b>	<b>\$ 184</b>	<b>\$ 785</b>	<b>\$ 742</b>
<b>Adjusted EBITDA Margin</b>				
Performance Solutions	24.5%	21.7%	22.9%	21.4%
Agricultural Solutions	21.5%	19.1%	19.9%	19.6%
<b>Total</b>	<b>23.0%</b>	<b>20.3%</b>	<b>21.4%</b>	<b>20.5%</b>

NOTE: Totals may not foot due to rounding

IV.  (amounts in millions)	<b>Capital Structure</b>		
	<b>Maturity</b>	<b>Coupon</b>	<b>December 31, 2016</b>
<b>Instrument</b>			
Corporate Revolver (\$500M)	6/7/2019	\$	—
Term Loan B4 - USD <sup>(1)</sup> <sup>(2)</sup>	6/7/2023	L + 400	1,471
Term Loan B5 - USD <sup>(2)</sup>	6/7/2020	L + 350	609
Term Loan C3 - EUR <sup>(1)</sup> <sup>(2)</sup>	6/7/2023	E + 375	454
Term Loan C4 - EUR <sup>(2)</sup>	6/7/2020	E + 325	734
Other Secured Debt			15
<b>Total First Lien Debt</b>			<b>3,282</b>
10.375% Senior Notes due 2021	5/1/2021	10.375%	500
6.5% Senior Notes due 2022	2/1/2022	6.5%	1,100
6.0% Senior Notes due 2023 (Euro)	2/1/2023	6.0%	368
Other Unsecured Debt			86
<b>Total Unsecured Debt</b>			<b>2,054</b>
<b>Total Debt</b>			<b>5,336</b>
Cash Balance as of 12/31/16			423
<b>Net Debt</b>			<b>\$ 4,913</b>
Shares Outstanding <sup>(3)</sup>			299
<b>Market Capitalization <sup>(4)</sup></b>			<b>\$ 2,929</b>
<b>Total Capitalization</b>			<b>\$ 7,842</b>

NOTE: Totals may not foot due to rounding

These term loans mature on June 7, 2023, provided that the Company prepays, redeems or otherwise retires and/or refinances in full its 6.50% USD Notes due 2022, as permitted under the Amended and Restated Credit Agreement, on (1) or prior to November 2, 2021, otherwise the maturity reverts to November 2, 2021.

Platform has swapped certain amounts of its floating term loans to fixed rate including \$1.1 billion of its USD tranches and €282 million of its Euro tranches. At December 31, 2016, approximately 36% of debt was floating and 64% was (2) fixed.

See "Calculation of Non-GAAP Adjusted Shares at December 31, 2016 (unaudited)" below the Comparable Adjusted (3) Earnings Per Share table.

(4) Based on Platform's closing price of \$9.81 at December 30, 2016.

**PLATFORM SPECIALTY PRODUCTS CORPORATION**  
**ADDITIONAL FINANCIAL INFORMATION (continued)**  
**(Unaudited)**

V.  (amounts in millions)	Selected Financial Data	
	Three Months Ended December 31, 2016	Twelve Months Ended December 31, 2016
Book Interest Expense, net	\$ 86	\$ 376
Cash Interest Paid	74	360
Book Income Tax (Benefit) Expense	(43)	22
Cash Income Taxes Paid	35	121
Capital Expenditures	24	56
Investments in Product Registrations	14	36
Proceeds from Sales of Assets (*)	—	13

NOTE: Totals may not foot due to rounding

(\*) Adjusted to exclude \$8 million of impact for the proceeds of a JV sale in Q3 2016.

**VI. Non-GAAP Measures**

For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company's historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statements of operations, balance sheets, or statements of cash flows of the company; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented.

To supplement the financial measures prepared in accordance with GAAP, Platform has provided in this release the following non-GAAP financial measures: adjusted EBITDA, adjusted EBITDA margin, adjusted EBITDA guidance, comparable net sales, comparable adjusted earnings per share, comparable adjusted EBITDA, comparable adjusted EBITDA margin and organic sales. Platform also evaluates and presents its results of operations on a comparable constant currency basis. Management believes that these measures provide useful information to investors by excluding certain items that it believes are not representative of the Company's business and including other items that it believes are useful in evaluating the Company's business; thereby providing a more complete understanding of the Company's operational results and a meaningful comparison of the Company's performance between periods and to its peers. When reconciled to the corresponding GAAP measures, these non-GAAP measures also help the Company's investors to understand the long-term profitability trends of the Company's businesses. Finally, these non-GAAP measures address questions the Company routinely receives from securities analysts, investors and other interested parties in the evaluation of companies in its industry and, in order to assure that all investors have access to the same data, the Company has determined that it is

appropriate to make this data available to all. Non-GAAP financial measures are however not prepared in accordance with GAAP, as they exclude certain items as described herein, and may not be indicative of the results that the Company expects to recognize for future periods. In addition, these non-GAAP financial measures may differ from measures that other companies may use. As a result, these non-GAAP financial measures should be considered in addition to, and not a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures included herein.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the financial tables as part of this release. The Company only provides Adjusted EBITDA guidance, organic sales growth and synergy potential on a non-GAAP basis and does not provide reconciliations of such forward-looking non-GAAP measures to GAAP, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including adjustments that could be made for restructuring, integration and acquisition-related expenses, share-based compensation amounts, adjustments to inventory and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant.

#### **Adjusted EBITDA:**

Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization, as further adjusted for additional items included in earnings that are not representative or indicative of our ongoing business as described in the footnotes to the non-GAAP measures reconciliations. Management believes Adjusted EBITDA provides investors with a more complete understanding of the long-term profitability trends of Platform's business, and facilitates comparisons of its profitability to prior and future periods.

#### **Comparable Adjusted EBITDA:**

Comparable adjusted EBITDA is defined as Adjusted EBITDA adjusted to reflect acquisitions and the related financings as though they had occurred on January 1, 2015 without the impact of purchase accounting. Adjusted EBITDA and comparable adjusted EBITDA are key metrics used by management to measure operating performance and trends. In particular, the exclusion of certain expenses in calculating adjusted EBITDA and comparable adjusted EBITDA facilitates operating performance comparisons on a period-to-period basis. Management believes comparable Adjusted EBITDA provides investors with a more complete understanding of the long-term profitability trends of Platform's business, and facilitates comparisons of its profitability to prior and future periods.

#### **Comparable Adjusted Earnings Per Share:**

Comparable adjusted earnings per share is defined as net loss attributable to common stockholders adjusted to reflect acquisitions and the related financings as though they had occurred on January 1, 2015 without the impact of purchase accounting, as well as other adjustments consistent with our definition of Adjusted EBITDA. We eliminate the amortization associated with intangibles assets recognized in purchase accounting for acquisitions and costs capitalized in connection with obtaining regulatory approval of our products ("registration rights") as part of ongoing operations. We deduct capital expenditures associated with obtaining these registration rights. Further, we adjust the effective tax rate to 35% as described in the notes to the reconciliation. For the quarters ended December 31, 2016 and 2015, the resulting comparable adjusted net income available to stockholders is divided by the number of shares of outstanding common stock as of December 31, 2016 plus the number of shares that would be issued if all convertible stock were converted to common stock, vested stock options were exercised, and awarded equity granted were vested as of December 31, 2016. For the full years 2016 and 2015, the resulting comparable adjusted net income available to stockholders is divided by the average of the four quarters of 2016. Comparable adjusted earnings per share is a key metric used by management to measure operating performance and trends. In particular, the exclusion of certain expenses in calculating comparable adjusted earnings per share facilitates operating performance comparisons on a period-to-period basis.

#### **Comparable Constant Currency:**

Our constant currency presentation excludes the impact of fluctuations in foreign currency exchange rates. Constant currency percentages are calculated by converting our current-period local currency financial results into U.S. Dollar using the prior period's exchange rates and comparing these adjusted amounts to our prior period reported results. The comparable constant currency presentation includes actual results adjusted to reflect acquisitions and related financings as though they had occurred on January 1, 2015 adjusted for the effects of purchase accounting on actual results. Management believes that this presentation provides a more complete understanding of the Company's operational results and a meaningful comparison of its performance between periods. However, this comparable financial information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the Company's acquisitions been completed as of the dates indicated, or that may be achieved in the future.

## **Comparable Net Sales**

Comparable net sales is defined as net sales adjusted for the sales of our acquisitions as though they had occurred on January 1, 2015. Management believes this measure provides investors with a more complete understanding of net sales trends by providing sales on a more consistent basis.

## **Organic Sales**

Organic sales is defined as comparable net sales excluding the impact of currency, metals price, divestitures and acquisitions, as applicable. Management believes this measure provides investors with a more complete understanding of the underlying net sales trends by providing comparable sales over differing periods on a consistent basis.

CONTACT:

Investor Relations Contact:

Carey Dorman  
Director - Corporate Development  
Platform Specialty Products Corporation  
1-561-406-8465

Media Contact:

Liz Cohen  
Weber Shandwick  
1-212-445-8044